
Oculis announces patient dosing in its diamond study DIAMOND, its first phase 3 study with OCS-01. bit.ly/3kzvZqW
English
VI Partners
2 posts

@VI_Partners_AG
VC firm based out of Switzerland. Investing in outstanding teams in Healthcare and Technology


